VapeAway® LLC Announces First Patient Enrolled in Clinical Study of Novel Vaping Cessation DeviceNEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- VapeAway® LLC, a healthcare company focused on developing innovative solutions for nicotine dependence due to vaping, today announced that the first patient has been enrolled in its clinical study evaluating its patented VapeAway® filter (technology) and fix bar (Fix+Bar) device system, a non-pharmacologic (“drug-free”) device designed to support vaping cessation.
